Nektar Therapeutics
NKTR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $98,427 | $90,122 | $92,055 | $101,907 |
| % Growth | 9.2% | -2.1% | -9.7% | – |
| Cost of Goods Sold | $30,686 | $36,644 | $21,635 | $24,897 |
| Gross Profit | $67,741 | $53,478 | $70,420 | $77,010 |
| % Margin | 68.8% | 59.3% | 76.5% | 75.6% |
| R&D Expenses | $120,908 | $114,162 | $218,323 | $400,269 |
| G&A Expenses | $76,751 | $77,417 | $92,333 | $122,844 |
| SG&A Expenses | $76,751 | $77,417 | $92,333 | $122,844 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$24,720 | -$676 | $0 | $0 |
| Operating Expenses | $172,939 | $190,903 | $310,656 | $523,113 |
| Operating Income | -$105,198 | -$137,425 | -$240,236 | -$446,103 |
| % Margin | -106.9% | -152.5% | -261% | -437.8% |
| Other Income/Exp. Net | -$14,002 | -$138,831 | -$124,747 | -$77,177 |
| Pre-Tax Income | -$119,200 | -$276,256 | -$364,983 | -$523,280 |
| Tax Expense | -$239 | -$200 | $3,215 | $557 |
| Net Income | -$118,961 | -$276,056 | -$368,198 | -$523,837 |
| % Margin | -120.9% | -306.3% | -400% | -514% |
| EPS | -8.68 | -21.79 | -29.51 | -42.9 |
| % Growth | 60.2% | 26.2% | 31.2% | – |
| EPS Diluted | -8.68 | -21.79 | -29.51 | -42.9 |
| Weighted Avg Shares Out | 13,711 | 12,667 | 12,476 | 12,220 |
| Weighted Avg Shares Out Dil | 13,711 | 12,667 | 12,476 | 12,220 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,500 | $19,009 | $6,783 | $2,731 |
| Interest Expense | $28,112 | $25,334 | $28,911 | $47,313 |
| Depreciation & Amortization | $4,391 | $7,815 | $12,200 | $14,146 |
| EBITDA | -$86,697 | -$243,107 | -$323,872 | -$461,821 |
| % Margin | -88.1% | -269.8% | -351.8% | -453.2% |